甲状腺癌与干扰素-γ、白介素-6关系的研究进展

doi:10.11904/j.issn.1002-3070.2017.01.019

摘要/Abstract

摘要： 甲状腺癌是内分泌系统最常见的恶性肿瘤,近年来因其发病率逐年上升引发了人们的高度重视。随着人们对甲状腺癌研究的不断深入,发现细胞因子在肿瘤的发生、发展中起到了关键作用。目前甲状腺癌的病因及发生机制尚未完全清楚,但甲状腺癌的发生与机体调节细胞免疫功能紊乱有关。细胞因子在整个过程中发挥了举足轻重的作用,其中细胞因子IFN-γ、IL-6与甲状腺癌关系尤为密切。

关键词: 甲状腺癌, 干扰素-γ, 白介素-6

Abstract: Thyroid cancer is the most common malignancy in the endocrine system.In recent years,the incidence of thyroid cancer has increased year by year,which sparked people's attention.With the development of thyroid cancer research,it is found that cytokines play a key role in the occurrence and development of tumor.At present,the cause of thyroid carcinoma and mechanism is not yet entirely clear,however,the occurrence of thyroid cancer is possiblely associated with the body regulating cellular immune dysfunction.Cytokines play an important role in the whole process,in which the relationship between cytokines IFN-γ,IL-6 and thyroid carcinoma is closely related.

Key words: Thyroid carcinoma, Interferon-γ, Interleukin-6

中图分类号:

R736.1

教玉颖综述, 付鹏审校. 甲状腺癌与干扰素-γ、白介素-6关系的研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 88-92.

JIAO Yuying, FU Peng. Research progress in relationships between thyroid carcinoma and interferon-γ and interleukin-6[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 88-92.

参考文献

1 Pellegriti G,Frasca F,Regalbuto C,et al.Wordwide increasing incidence of thyroid cancer:update on epidemiology and risk factors[J].Cancer Epidemiol,2013,2013(1):965212-965222.
2 Muller-Hubenthal B,Azemar M,Lorenzen D,et al.Tumour biology:tumour-associated inflammation versus antitumor immunity[J].Anticancer Res,2009,29(11):4795-4805.
3 Cunha LL,Tincani Aj,Assumpcao LV,et al.Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer[J].Clinics(Sao Paulo),2011,66(7):1203-1208.
4 Lumashi F,Basso SM,Orlando R.Cytokines,thyroid diseases and thyroid cancer[J].Cytokine,2010,50(3):229-233.
5 Bodelon C,Polley MY,Kemp TJ,et al.Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer[J].Ann Oncol,2013,24(8):2073-2079.
6 Mazumder A,Rosenberg SA.Successful immunotherapy of nature killer resistant estalished pubmonary melanoma metastases by the intravenous adoptive transfer of sysgnic lymphocytes activated in vitro by interlenkin 2[J].J Exp Med,1984,159(2):495-507.
7 Zivancevic-Simonovic S,Mihaljevic O,Majstorovic I,et al.Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis[J].Cancer Immunol Immunother,2015,64(8):1011-1019.
8 Simonovic SZ,Mihaljevic O,Majstorovic I,et al.Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer:elevated Th2/Th9 production before and reduced Th2 cytokine production after radioactive iodine therapy[J].Cancer Immunol Immunother,2015,64(1):75-82.
9 Kobawala TP,Trivedi TI,Gajjar KK,et al.Significance of interleukin-6 in papillary thyroid carcinoma[J].J Thyroid Res,2016,2016(6):1-12.
10 Miyata T,Honma R,Sato A,et al.Effect of rCaIFN-γ pretreatment on propofol-isoflurane suppression of NK cytotoxic activity in the peripheral blood of dogs[J].Res Vet Sci,2015,98:25-29.
11 Liu J,Duan Y,Cheng X,et al.IL-17 is associated with poor prognosis and promotes via stimulating VEGF production of cancer cells in colorectal carcinoma[J].Biochem Biophys Res Commun,2011,407(2):348-354.
12 Lv N,Gao Y,Guan H,et al.Inflammatory mediators,tumor necrosis factor-α and interferon-γ,induce EMT in human PTC cell lines[J].Oncol Lett,2015,10(4):2591-2597.
13 Hossain MS,Bhimani C,Zhengjia C,et al.Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients[J].Cancer Res,2011,71(8):5525-5535.
14 Kura Y,De Velasco MA,Kobayashi Y,et al.Interleukin-6(IL-6)as a therapeutic target in prostate cancer[J].Cancer Res,2013,73(8):1226-1238.
15 Qi YF,Huang YX,Wang HY,et al.Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling[J].BMC Bioinformatics,2013,14(1):41-62.
16 Croker BA,Kiu H,Nicholson SE.SOCS regulation of the JAK/STAT signalling pathway[J].Semin Cell Dev Bio,2008,19(4):414-422.
17 Francipane MG,Eterno V,Spina V,et al.Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy[J].Cancer Res,2009,69(15):6141-6148.
18 Croker BA,Krebs DL,Zhang JG,et al.SOCS3 negatively regulates IL-6 signaling in vivo[J].Nat Immunol,2003,4(6):540-545.
19 Mali SB.Review of STAT3(Signal Transducers and Activators of Transcription)in head and neck cancer[J].Oral Oncol,2015,51(6):565-569.
20 Fan TF,Bu LL,Wang WM,et al.Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC[J].Oncotarget,2015,6(41):43581-43593.
21 Kolosenko I,Grander D,Tamm KP.IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma[J].Curr Med Chem,2014,21(26):3042-3047.
22 Pencik J,Wiebringhaus R,Susani M,et al.IL-6/STAT3/ARF:the guardians of senescence,cancer progression and metastasis in prostate cancer[J].Swiss Med Wkly,2015,145(4):14215-14225.
23 Lumachi F,Basso SM,Orlando R.Cytokines,thyroid diseases and thyroid cancer[J].Cytokine,2010,50(3):229-233.
24 Zhang J,Gill A,Atmore B,et al.Upregulation of the signal transducers and activators of transcription 3(STAT3)pathway in lymphatic metastases of papillary thyroid cancer[J].Int J Clin Exp Pathol,2011,4(4):356-362.
25 McFarland BC,Gray GK,Nozell SE,et al.Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells[J].Mol Cancer Res,2013,11(5):494-505.
26 Grabner B,Schramek D,Mueller KM,et al.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis[J].Nat Commun,2015,6(5):6285-6299.
27 Couto JP,Daly L,Almeida A,et al.STAT3 negatively regulates thyroid tumorigenesis[J].Proc Natl Acad Sci USA,2012,109(35):2361-2370.
28 Bluyssen HA,Rastmanesh MM,Tilburgs C,et al.IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells[J].Am J of Physiol Cell Physiol,2010,299(2):354-362.
29 Costa-Pereira AP,Tininini S,Strobl B,et al.Mutational switch of an IL-6 response to an interferon-gamma-like response[J].Proc Natl Acad Sci USA,2002,99(12):8043-8047.
30 Su Z,Sun Y,Zhu H,et al.Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis[J].Immunol Re,2014,58(1):118-124.
31 Guarino V,Castellone MD,Avilla E,et al.Thyroid cancer and inflammation[J].Mol Cell Endocrinol,2010,321(1):94-102.
32 Koperek O,Asari R,Niederle B,et al.Desmoplastic stromal reaction in papillary thyroid microcarcinoma[J].Histopathology,2011,58(6):919-924.
33 Provatopoulou X,Georgiadou D,Sergentanis TN,et al.Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res,2014,63(8):667-674.
34 Toral P,Trupti I,Kinjal K,et al.Significance of Interleukin-6 in papillary thyroid carcinoma[J].J Thyroid Res,2016,2016(6):1-12.
35 Cil E,Kumral A,Vural P,et al.Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer[J].Mol Biol Rep,2014,41(5):3091-3097.
36 Lun Y,Wu X,Xia Q,et al.Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis[J].Otolaryngol Head Neck Surg,2013,148(3):396-402.
37 Schaper F,Rose-John S.Interleukin-6:Biology,signaling and strategies of blockade[J].Cytokine Growth Factor Rev,2015,26(5):475-487.
38 Atsumi T,Singh R,Sabharwal L,et al.Inflammation amplifier,a new paradigm in cancer biology[J].Cancer Res,2014,74(1):8-14.
39 Guarino V,Castellone MD,Avilla E,et al.Thyroid cancer and inflammation[J].Mol Cell Endocrinol,2010,321(1):94-102.
40 Engelmann D,Koczan D,Ricken P,et al.Transcriptome analysis in mouse tumors induced by RetMEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance[J].Endocr Relat Cancer,2009,16(1):211-224.
41 Knauf JA,Sartor MA,Medvedovic M,et al.Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF-β signaling[J].Oncogene,2011,30(30):3153-3162.

[1]	孔繁巍综述, 赵长久审校. 分化型甲状腺癌碘131治疗后的外周血细胞改变[J]. 实用肿瘤学杂志, 2018, 32(5): 476-479.
[2]	程卫,赵华. 重组人促甲状腺激素辅助¹³¹I在儿童和青少年分化型甲状腺癌的临床研究[J]. 实用肿瘤学杂志, 2016, 30(4): 309-313.
[3]	冯卓颖, 鹿瑶, 苏雁欣, 都杨. Logistic回归模型在超声评价甲状腺结节良恶性及淋巴转移的应用研究[J]. 实用肿瘤学杂志, 2015, 29(5): 385-389.
[4]	丁兆明, 陈琢, 陈丽丽. 心理社会危险因素与甲状腺癌的相关性研究[J]. 实用肿瘤学杂志, 2015, 29(5): 414-419.
[5]	孙冀, 苗素生, 裴荣综述, 毛雄辉审校. RET基因在肿瘤中的研究现状和展望[J]. 实用肿瘤学杂志, 2015, 29(5): 467-470.
[6]	王迪¹, 何月涵², 王兴华¹, 于红波¹, 王玉君¹, 崔亚利¹. 青少年分化型甲状腺癌¹³¹I治疗的临床观察[J]. 实用肿瘤学杂志, 2015, 29(3): 193-196.
[7]	田淞宇, 秦华东, 石铁锋, 刘垚, 孙宇. 乳腺癌与甲状腺癌相关性的探讨[J]. 实用肿瘤学杂志, 2011, 25(4): 333-335.
[8]	焦明秀综述, 崔亚利审校. 肿瘤乏氧显像在预测甲状腺癌内放疗疗效的临床应用[J]. 实用肿瘤学杂志, 2009, 23(6): 593-596.
[9]	陈征综述, 赵雪松审校. p16、p27和Cyclin D1在分化型甲状腺癌的表达研究^△[J]. 实用肿瘤学杂志, 2009, 23(4): 389-393.
[10]	王玉君;赵彦辉;崔亚利. 99mTc-MIBI全身显像在131I治疗分化型甲状腺癌转移灶中的应用价值[J]. 实用肿瘤学杂志, 2008, 22(04): 337-338.
[11]	王翠芳;孙洁;滕猛;宦大为. RET、HBME-1和Ki67在甲状腺良、恶性肿瘤中的表达[J]. 实用肿瘤学杂志, 2007, 21(05): 427-429.
[12]	高虹;丛琦;全成实;郭晓峰. 甲状腺癌组织中凋亡相关蛋白Fas,FasL,Bcl-2和Bax的表达及意义[J]. 实用肿瘤学杂志, 2005, 19(04): 273-275.
[13]	何洪江;贾深汕. 甲状腺癌组织中诱导型一氧化氮合酶与CD105的表达及其意义[J]. 实用肿瘤学杂志, 2004, 18(06): 435-437.
[14]	王琤;周义林;张军盛;徐慧琴. 99mTc-MIBI显像对甲状腺结节良恶性的鉴别诊断价值[J]. 实用肿瘤学杂志, 2003, 17(03): 195-196.
[15]	李军;张茹斌;商道辉;陈淑丽. 老年人甲状腺癌34例分析[J]. 实用肿瘤学杂志, 2002, 16(04): 265-267.